

PEER-REVIEW REPORT

Name of journal: World Journal of Clinical Cases

Manuscript NO: 55298

Title: Adjuvant nab-paclitaxel plus gemcitabine vs gemcitabine alone for resected pancreatic ductal adenocarcinoma: A single center experience in China

Reviewer's code: 03766580

Position: Editorial Board

Academic degree: MD, PhD

Professional title: Associate Professor

Reviewer's Country/Territory: Greece

Author's Country/Territory: China

Manuscript submission date: 2020-03-17

Reviewer chosen by: Jin-Zhou Tang (Quit in 2020)

Reviewer accepted review: 2020-04-12 15:02

Reviewer performed review: 2020-04-12 15:07

Review time: 1 Hour

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input checked="" type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input type="checkbox"/> Grade A: Priority publishing <input type="checkbox"/> Grade B: Minor language polishing <input checked="" type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input checked="" type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input type="checkbox"/> Yes <input type="checkbox"/> No
Peer-reviewer statements	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

SPECIFIC COMMENTS TO AUTHORS

The present trial is a retrospective trial which was not randomized but the cases were selected by random. Therefore, there is a selection bias in the reported results. Additionally there is no comparison with previous reported results, while the APACT study has reported negative results regarding the nab-paclitaxel - based regimen. A better presentation of the results could be re-evaluated for potential publication.

PEER-REVIEW REPORT

Name of journal: World Journal of Clinical Cases

Manuscript NO: 55298

Title: Adjuvant nab-paclitaxel plus gemcitabine vs gemcitabine alone for resected pancreatic ductal adenocarcinoma: A single center experience in China

Reviewer's code: 02733628

Position: Editorial Board

Academic degree: MD

Professional title: Associate Professor, Doctor, Surgeon

Reviewer's Country/Territory: Turkey

Author's Country/Territory: China

Manuscript submission date: 2020-03-17

Reviewer chosen by: Jin-Zhou Tang (Quit in 2020)

Reviewer accepted review: 2020-04-14 16:24

Reviewer performed review: 2020-04-14 16:37

Review time: 1 Hour

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input checked="" type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input type="checkbox"/> Yes <input type="checkbox"/> No
Peer-reviewer statements	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

SPECIFIC COMMENTS TO AUTHORS

Dear author, Thank you for sharing your article entitled "Adjuvant Nab-paclitaxel plus Gemcitabine versus Gemcitabine Alone for Resected Pancreatic Ductal Adenocarcinoma: A Single Center Experience in China" Your article is good in grammar and scientific writing rules. The topic is actual and well described. Sincerely